Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|March 15, 2005
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination StudyGraeme J Moyle, Edwin DeJesus, Pedro Cahn, et al.
AIDS (London, England)|October 4, 2008
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patientsJoel E Gallant, Jonathan A Winston, Edwin DeJesus, et al.
Clinical Drug Investigation|September 3, 2016
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical PracticePhilip Lackey, Anthony Mills, Felix Carpio, et al.
AIDS Patient Care and Stds|February 17, 2010
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DFSally L Hodder, Karam Mounzer, Edwin Dejesus, et al.
AIDS (London, England)|April 12, 2005
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresMargaret Johnson, Beatriz Grinsztejn, Claudia Rodriguez, et al.
Clinical Therapeutics|July 25, 2006
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on studyJoseph C Gathe, Robin Wood, Ian Sanne, et al.
HIV Clinical Trials|December 4, 2010
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trialCalvin Cohen, Edwin Dejesus, Anthony Lamarca, et al.
The Journal of Infectious Diseases|March 20, 2004
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virusGregory J Dore, David A Cooper, Anton L Pozniak, et al.
AIDS (London, England)|December 5, 2015
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virusMelanie Thompson, Michael Saag, Edwin DeJesus, et al.
AIDS Research and Human Retroviruses|January 26, 2018
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of TreatmentEdwin DeJesus, Bernard Haas, Sorana Segal-Maurer, et al.
Pageof 16